Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development
Andrew D Cook, Jarrad Pobjoy, Stefan Steidl, Manuela Duerr, Emma L Braine, Amanda L Turner, Derek C Lacey, John A Hamilton
Arthritis Research & Therapy | BIOMED CENTRAL LTD | Published : 2012
We thank Jennifer Davis and Lara Mizhiritsky for assistance with the maintenance and care of the mice, and Amanda J Fosang for the antibody against DIPEN. This work was supported by grants from MorphoSys AG and the National Health and Medical Research Council (NHMRC), and by a NHMRC Senior Principal Research Fellowship (JAH).SS is a full-time employee of MorphoSys AG, Germany. JAH has received consulting fees from MorphoSys AG, Germany (less than0,000 a year). MD was a full-time employee of MorphoSys AG, Germany, until 2011. MorphoSys AG, Germany, have partially funded the work in this manuscript. Patent applications from the University of Melbourne (ADC, JAH) are pending on the treatment of OA and pain by using GM-CSF antagonists. MorphoSys AG hold patents on anti-GM-CSF antibodies.